Kanada - angličtina - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 94mcg - peginterferon beta-1a 94mcg - interferons

Kanada - angličtina - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 125mcg - peginterferon beta-1a 125mcg - interferons

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

6million units - interferon beta-1a - solution for injection - 12mega u/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

6million units - interferon beta-1a - solution for injection - 12mega u/1ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 30ug;   - injection with diluent - 30 mcg - active: interferon beta-1a 30ug   excipient: albumin dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bayer new zealand limited - interferon beta-1b 0.25mg (20% excess in quantity filled) - injection with diluent - 8 miu - active: interferon beta-1b 0.25mg (20% excess in quantity filled) excipient: albumin hydrochloric acid mannitol sodium hydroxide hydrochloric acid sodium chloride water for injection - betaferon is indicated for: · the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, · the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. · the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 15 miu/ml - solution for injection - 18 miu - active: interferon alfa-2b 15 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 25 miu/ml - solution for injection - 30 miu - active: interferon alfa-2b 25 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;